How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
- PMID: 32021319
- PMCID: PMC6954843
- DOI: 10.2147/IDR.S234353
How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
Abstract
Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The practice of phage therapy, the application of phages to treat bacterial infections, has been around for approximately a century. Phage therapy relies on using lytic bacteriophages and purified phage lytic proteins for treatment and lysis of bacteria at the site of infection. Current research indicates that phage therapy has the potential to be used as an alternative to antibiotic treatments. It is noteworthy that, whether phages are used on their own or combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and phages mechanism for treating bacterial infections and the most recent studies on potential phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria.
Keywords: MDR; PDR; XDR; bacteriophage; drug resistant.
© 2020 Taati Moghadam et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):162-173. doi: 10.4292/wjgpt.v8.i3.162. World J Gastrointest Pharmacol Ther. 2017. PMID: 28828194 Free PMC article. Review.
-
Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.Front Microbiol. 2018 May 4;9:775. doi: 10.3389/fmicb.2018.00775. eCollection 2018. Front Microbiol. 2018. PMID: 29780361 Free PMC article. Review.
-
Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.J Antimicrob Chemother. 2014 Sep;69(9):2326-36. doi: 10.1093/jac/dku173. Epub 2014 May 28. J Antimicrob Chemother. 2014. PMID: 24872344 Review.
-
Bacteriophage Effectively Rescues Pneumonia Caused by Prevalent Multidrug-Resistant Klebsiella pneumoniae in the Early Stage.Microbiol Spectr. 2022 Oct 26;10(5):e0235822. doi: 10.1128/spectrum.02358-22. Epub 2022 Sep 27. Microbiol Spectr. 2022. PMID: 36165773 Free PMC article.
-
Bacteriophage as a Novel Therapeutic Weapon for Killing Colistin-Resistant Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Bacteria.Curr Microbiol. 2021 Dec;78(12):4023-4036. doi: 10.1007/s00284-021-02662-y. Epub 2021 Oct 11. Curr Microbiol. 2021. PMID: 34633487 Free PMC article. Review.
Cited by
-
Genomic and Proteomic Analysis of Six Vi01-like Phages Reveals Wide Host Range and Multiple Tail Spike Proteins.Viruses. 2024 Feb 13;16(2):289. doi: 10.3390/v16020289. Viruses. 2024. PMID: 38400064 Free PMC article.
-
Antibiotic resistance and tolerance: What can drug delivery do against this global threat?Drug Deliv Transl Res. 2024 Feb 10. doi: 10.1007/s13346-023-01513-6. Online ahead of print. Drug Deliv Transl Res. 2024. PMID: 38341386
-
Isolation and Phenotypic Characterization of Virulent Bacteriophages Against Multidrug-Resistant Escherichia coli and Its Phage-Resistant Variant from Sewage Sources.Infect Drug Resist. 2024 Jan 25;17:293-303. doi: 10.2147/IDR.S441085. eCollection 2024. Infect Drug Resist. 2024. PMID: 38293311 Free PMC article.
-
Antimicrobial resistance expansion in pathogens: a review of current mitigation strategies and advances towards innovative therapy.JAC Antimicrob Resist. 2023 Dec 11;5(6):dlad127. doi: 10.1093/jacamr/dlad127. eCollection 2023 Dec. JAC Antimicrob Resist. 2023. PMID: 38089461 Free PMC article. Review.
-
Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle.World J Clin Cases. 2023 Nov 6;11(31):7530-7542. doi: 10.12998/wjcc.v11.i31.7530. World J Clin Cases. 2023. PMID: 38078132 Free PMC article. Review.
References
-
- Jain S. Emergence of colistin resistance among gram negative bacteria in urinary tract infections from super specialty hospital of North India. Int J Infect Dis. 2018;73:133. doi:10.1016/j.ijid.2018.04.3716 - DOI
Publication types
LinkOut - more resources
Full Text Sources
